Interleukin-2: its rationale and role in the treatment of patients with cancer.
Rubin
J T
JT
Department of Surgery, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D005544:Forecasting; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000502:physiology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
D000276:Adjuvants, Immunologic; D016207:Cytokines; D007376:Interleukin-2; D015375:Receptors, Interleukin-2